Shattuck Labs, Inc. (NASDAQ:STTK) Shares Sold by Redmile Group LLC

Redmile Group LLC trimmed its holdings in Shattuck Labs, Inc. (NASDAQ:STTK) by 1.3% during the fourth quarter, HoldingsChannel reports. The firm owned 5,539,724 shares of the company’s stock after selling 75,765 shares during the period. Redmile Group LLC owned about 0.12% of Shattuck Labs worth $6,703,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in STTK. Adage Capital Partners GP L.L.C. increased its holdings in shares of Shattuck Labs by 61.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after purchasing an additional 1,775,000 shares during the last quarter. 683 Capital Management LLC purchased a new stake in Shattuck Labs in the 4th quarter valued at $1,270,000. Prosight Management LP raised its holdings in shares of Shattuck Labs by 15.1% during the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after acquiring an additional 873,409 shares during the period. Takeda Pharmaceutical Co. Ltd. acquired a new position in shares of Shattuck Labs during the 4th quarter valued at about $624,000. Finally, Bank of America Corp DE grew its holdings in shares of Shattuck Labs by 135.0% in the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock valued at $226,000 after purchasing an additional 107,491 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Stock Performance

Shares of STTK stock opened at $0.91 on Thursday. The firm has a market cap of $43.35 million, a P/E ratio of -0.59 and a beta of 1.74. The firm’s 50 day moving average price is $0.99 and its 200-day moving average price is $1.14. Shattuck Labs, Inc. has a one year low of $0.69 and a one year high of $9.08.

Shattuck Labs (NASDAQ:STTK) last posted its earnings results on Thursday, May 1st. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. As a group, research analysts predict that Shattuck Labs, Inc. will post -1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on STTK shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Shattuck Labs in a research note on Thursday, March 27th. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a report on Monday, March 17th. Leerink Partners began coverage on Shattuck Labs in a research note on Monday, March 17th. They set an “outperform” rating and a $4.00 target price for the company. Finally, HC Wainwright restated a “neutral” rating on shares of Shattuck Labs in a research report on Thursday, March 27th. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Shattuck Labs has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.